MATCHPOINT - Medulloblastoma Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Granulocyte macrophage colony stimulating factor (Primary) ; Pembrolizumab (Primary) ; Temozolomide (Primary)
- Indications Medulloblastoma
- Focus Adverse reactions
- Acronyms MATCHPOINT
- 03 Feb 2025 New trial record